Kelch-like protein 6 (KLHL6) is an uncharacterized gene mutated in diffuse large B-cell lymphoma (DLBCL). Here we report that KLHL6 assembles with cullin3 to form a functional cullin-RING ubiquitin ligase. Mutations in KLHL6 inhibit its ligase activity by disrupting the interaction with cullin3. Loss of KLHL6 favours DLBCL growth and survival both in vitro and in xenograft models. We further established that the mRNA decay factor roquin2 is a substrate of KLHL6. Degradation of roquin2 is dependent on B-cell receptor activation, and requires the integrity of the Tyr691 residue in roquin2 that is essential for its interaction with KLHL6. A non-degradable roquin2(Y691F) mutant requires its RNA-binding ability to phenocopy the effect of KLHL6 loss. Stabilization of roquin2 promotes mRNA decay of the tumour suppressor and NF-κ B pathway inhibitor, tumour necrosis factor-α -inducible gene 3. Collectively, our findings uncover the tumour suppressing mechanism of KLHL6.
B
-cell cancers hijack protein ubiquitylation and degradation pathways to promote growth and survival, as shown by the successful use of a proteasome inhibitor (bortezomib) and E3 ubiquitin ligase inhibitor (lenalinomide) as a treatment for multiple myeloma and mantle cell lymphoma 1 . Despite notable progress, much remains to be explored in the field of ubiquitin and the molecular mechanisms of tumorigenesis.
KLHL6 is a member of the bric-a-brac/tramtrack/broad-complex (BTB) domain family of proteins with a lymphoid tissue-restricted expression pattern 2, 3 . Whole-genome and exome sequencing have revealed cancer-associated mutations in KLHL6 in B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) [4] [5] [6] [7] ; however, the relevance of these mutations as well as the molecular function of KLHL6 remains unknown.
DLBCL is the most common type of lymphoid malignancies with two distinct molecular subtypes: activated B cell-like (ABC) and germinal centre B cell-like (GCB) lymphoma 8, 9 . ABC-DLBCLs depend on hyperactivation of the inhibitor of Iκ B kinase (IKK) and the NF-κ B transcription factor program for their proliferation and survival 10, 11 . This is revealed by the frequent mutations in the BCR pathway, including activating mutations in positive (CD79A, CD79B and CARD11 12, 13 ) and inactivating mutations in negative (tumour necrosis factor-α -inducible gene 3, TNFAIP3 [12] [13] [14] [15] ) NF-κ B regulators. How KLHL6 contributes to the pathology of human DLBCL and whether it influences NF-κ B activation are currently unknown.
Regulatory networks that promote cancer progression modulate gene expression at the level of mRNA stability 16, 17 . The RNAbinding proteins roquin1 and roquin2 (hereafter roquin1 and roquin2) promote mRNA decay via recognition of stem-loop motifs in the 3′ untranslated region (UTR) of target mRNAs 18, 19 .
Through this recognition, roquins recruit the CCR4-CAF1-NOT complex, leading to mRNA deadenylation and subsequent destabilization [18] [19] [20] [21] [22] . In T cells, roquin proteins contribute to immune homeostasis by promoting the decay of inducible T-cell costimulator (ICOS). However, the role of roquin in B-cell cancers has not been investigated 18, 23 .
Here, we demonstrate that KLHL6 is an E3 ligase for roquin2. Cancer-associated mutations in KLHL6 inhibit its ubiquitin ligase activity and inactivation or loss of KLHL6 in ABC-DLBCL cells promotes cancer cell growth and survival through stabilization of roquin2 and subsequent decay of TNFAIP3 mRNA. This study shows how ABC-DLBCL cells hijack the ubiquitin pathway to promote their proliferation via alteration of the mRNA decay process.
Results
KLHL6 mutations in human DLBCL abolish its catalytic function as cullin3-RING-ligase complex. Analysis of genomic databases of human patients with mature B-cell cancers revealed mutations in KLHL6 in patients with DLBCL (http://cancergenome.nih.gov/ and refs [4] [5] [6] [7] , chronic lymphocytic leukaemia 24 and multiple myeloma 25 (Fig. 1a ). DLBCL cohorts displayed the highest rate of genetic mutations ( Fig. 1a ), which are similarly stratified among GCB-DLBCL, ABC-DLBCL and uncharacterized DLBCL (Fig. 1b) . Most mutations in DLBCL are missense and monoallelic, with a low number of non-sense and frameshift mutations ( Fig. 1c , Supplementary Table 1 and refs [4] [5] [6] [7] . The majority of mutations clusters near and inside the BTB-domain of KLHL6 with mutational hotspots in Leu65 and Leu90 (Fig. 1c) . Moreover, re-analysis of published single-nucleotide polymorphism (SNP) array data 26 revealed infrequent deletion of the KLHL6 locus ( Supplementary Fig. 1a ), while approximately 6% of DLBCL tumours displayed lower expression of the KLHL6 transcript ( Supplementary Fig. 1b ).
To understand the impact of these cancer-associated mutations, we compared the protein interactome of KLHL6(WT) to that of the cancer mutant KLHL6(L65P). Flag-KLHL6(WT) or Flag-KLHL6(L65P) complexes were immunopurified from two cell lines (HEK293T and ARP-1) and the tryptic digestion of each protein eluate was analysed by mass spectrometry (Supplementary Table  2 ). Unique spectral counts corresponding to cullin3 were identified in KLHL6(WT), but not in KLHL6(L65P), immunoprecipitates ( Fig. 1d and Supplementary Table 2 ).
We validated our proteomic analysis via immunoprecipitation of KLHL6 with endogenous cullin3, but not cullin1, in HEK293T cells (Fig. 1e ). By carrying out an in vitro ubiquitylation assay, we found that KLHL6 promoted self-ubiquitylation and, notably, its BTBdomain alone (KLHL6(Δ Kelch)) was sufficient for catalysing selfpolyubiquitylation to a greater degree (Fig. 1f ). These data suggest that KLHL6 assembles a functional cullin3-RING-ligase (CRL3) complex 27 (Fig. 1j ).
We then investigated the effect of DLBCL-associated BTBdomain mutations on KLHL6 ligase assembly and activity. All mutations tested (L65P, S94I, F97L) disrupted binding to cullin3 ( Fig. 1g) and consequently led to a loss of self-polyubiquitylation in vitro (Fig. 1h) . Correspondingly, the protein levels of BTBdomain KLHL6 mutants were remarkably high at steady state and displayed extended half-lives compared to those of wild-type KLHL6 (Fig. 1i ), suggesting loss of KLHL6 self-ubiquitylation affects its turnover in cells. (UBCH5C) and ATP. g, Immunoblot analysis of immunoprecipitated Flag-tagged wild-type (WT) KLHL6, BTB-domain mutant KLHL6 (L65P, S94I and F97L) or empty vector in HEK293T cells. h, In vitro ubiquitylation reaction of immunopurified wild-type and BTB-domain mutant (L65P, S94I and F97L) Flag-KLHL6. i, Left, immunoblot analysis of whole-cell lysates from GFP + OCI-Ly10 KLHL6 −/− cells (clone-derived) retrovirally transduced with cDNAs encoding an empty vector, wild-type KLHL6 or BTB-domain mutant KLHL6 (L65P, S94I and F97L) and carrying a GFP marker. Cells were treated with cycloheximide (CHX) for the indicated times. Right, quantification of KLHL6 protein levels. Data are mean ± s.d., n = 3 independent experiments, two-way ANOVA, ***P ≤ 0.001; ****P ≤ 0.0001. j, Schematic model of cullin3-RING-ligase (CRL3)-KLHL6 complex. Unprocessed scans of immunoblots in e-i are shown in Supplementary Fig. 8 , and statistical source data and exact P values for i can be found in Supplementary Table 6 . Unless otherwise noted, immunoblots are representative of three independent experiments.
KLHL6 interacts with and promotes the ubiquitylation and degradation of roquin2. Because KLHL6(L65P) is unable to promote ubiquitylation, we reasoned that it might trap (that is, interact with but not ubiquitylate) substrates ( Fig. 1j ). By ranking proteins by the number of unique spectral counts, we identified roquin2 as a potential substrate ( Fig. 2a and Supplementary Table 2 ). Supplementary Fig. 2d . f, KLHL6 +/+ and KLHL6 −/− U2932 cells (clone-derived) were processed as in e. Low exposure (l.e.) and high exposure (h.e.) blots are shown. Quantification and statistical analysis is shown in Supplementary  Fig. 2d Supplementary Fig. 8 , and source data for i can be found in Supplementary Table 6 . Unless otherwise noted, immunoblots are representative of three independent experiments.
In agreement with our proteomic data, KLHL6 specifically coimmunoprecipitated endogenous roquin2 in HEK293T cells (Fig. 2b) . The reciprocal co-immunoprecipitation experiments confirmed that roquin2, but not roquin1, is a KLHL6 interactor ( Fig. 2c ). This complex was also detectable at an endogenous level in DLBCL cells ( Supplementary Fig. 2a ). Importantly, interaction between KLHL6 and roquin2 required the intact Kelch domain in KLHL6 ( Supplementary Fig. 2b ), further supporting a substrate-like interaction 28 .
In DLBCL cell lines, abundance of KLHL6 and roquin2 displayed an inverse correlation ( Fig. 2d and Supplementary Fig. 2c ). To investigate whether KLHL6 controls roquin2 protein levels, we assessed roquin2 protein turnover upon knockdown or knockout of KLHL6 in OCI-LY10 and U2932 cells, respectively. In both cases, downregulation of KLHL6 significantly extended the half-life of roquin2, but not that of roquin1 ( Fig. 2e,f and Supplementary Fig. 2d ).
Gain-of-function experiments showed that re-expression of KLHL6 in cell lines with low KLHL6 expression (that is, HEK293T and HBL1 cells) downregulated roquin2 protein levels ( Supplementary  Fig. 2e ). Moreover, BTB-domain mutants were incapable of inducing roquin2 downregulation ( Supplementary Fig. 2f ). Notably, co-expression of KLHL6(WT) along with BTB-domain mutants still promoted roquin2 degradation, suggesting that these mutations are not dominant negative ( Supplementary Fig. 2g ).
Next, we used B-cell lymphoma cell lines that have endogenous KLHL6 mutations. VAL cells harbour two BTB-domain mutations: N60T and T72R ( Fig. 2g ). Binding analysis revealed that only the KLHL6(T72R) mutant lost interaction with cullin3 ( Fig. 2g ), whereas the KLHL6(N60T) mutant did not. Knockdown of KLHL6 in VAL cells did not result in roquin2 accumulation ( Fig. 2h) , whereas re-expression of KLHL6 induced roquin2 downregulation ( Fig. 2j ). In VAL cells, expression of KLHL6 at the mRNA level was comparatively low (Fig. 2i ). This suggests that VAL cells have one KLHL6 allele that is inactivated by a mutation in the BTB-domain and additional downregulation of KLHL6 mRNA. By contrast, mutations in KLHL6 in SUDHL10 cells had no impact on KLHL6 function ( Fig. 2g-j) .
Last, to explore whether KLHL6 directly controls roquin2 ubiquitylation in vitro, we incubated immunopurified KLHL6-roquin2 complex with a ubiquitylation mix. High-molecular weight species of roquin2 were detected with the KLHL6(WT) complex, but not with KLHL6(L65P) ( Fig. 2k ). Correspondingly, ubiquitylation of roquin2 was abolished in KLHL6 −/− cell lines in vivo ( Supplementary Fig. 2h ). Supplementary Fig. 8 , and statistical source data and exact P values for a-e can be found in Supplementary Table 6 . Unless otherwise noted, immunoblots are representative of three independent experiments.
KLHL6 functions as a tumour suppressor in ABC-DLBCL by regulating its growth and survival.
Although mutations in KLHL6 occur at a similar rate in GCB-and ABC-DLBCL ( Fig. 1b ), low KLHL6 expression correlated with a significantly poorer survival in ABC-DLBCL patients ( Fig. 3a) as previously reported 29, 30 .
To assess the biological effect of KLHL6 loss in ABC-DLBCL lines, we infected Cas9-expressing U2932, OCI-LY10 and TMD8 cells with lentiviruses encoding three different guide RNAs (gRNAs) targeting the KLHL6 gene locus. Ablation of KLHL6 resulted in an increase in cell proliferation and a decrease in apoptosis ( Fig. 3b,c) . This effect was confirmed in three-dimensional cultures as measured by a larger number and size of colonies ( Supplementary Fig. 3a,b ). To rule out the possible off-target effects of gRNAs, we used short hairpin RNA (shRNA)-mediated knockdown of KLHL6 in U2932 and OCI-LY10 and observed similar results ( Supplementary Fig. 3c-f ).
To investigate the role of cancer mutations in cell growth, we reexpressed KLHL6(WT), KLHL6 BTB-domain mutants or an empty vector (EV) in a clonally derived U2932 KLHL6 −/− cell line ( Fig. 3d ). Whereas re-expression of KLHL6(WT) decreased cell proliferation, expression of KLHL6 BTB-domain mutants phenocopied loss of KLHL6, confirming that these mutations resulted in loss of function. In xenograft models, expression of KLHL6(WT) decreased tumour burden whereas expression of KLHL6(S94I) led to a similar tumour burden compared to tumours generated from KLHL6 −/− cells expressing the empty vector ( Fig. 3e) .
A non-degradable roquin2 mutant phenocopies loss of KLHL6.
We mapped the KLHL6 binding motif in roquin2. By performing mutagenesis experiments, we identified that a region in roquin2 between amino acids 640 and 700 was necessary for the interaction with KLHL6 ( Fig. 4a,b ). More refined deletions narrowed the interaction domain between amino acids 690 and 695 ( Fig. 4c ). Alanine scanning mutagenesis of the individual residues surrounding the 691-704 region revealed that a conserved tyrosine residue, in position 691, was required for KLHL6-roquin2 interaction (Fig. 4d ). In vitro binding assays confirmed that a roquin2 peptide consisting of residues 686-700 directly interacts with KLHL6 ( Supplementary  Fig. 4a-d ). Mutating Tyr691 to alanine or phenylalanine impaired the ability of roquin2 to co-immunoprecipitate with KLHL6 in vivo and in vitro ( Fig. 4e and Supplementary Fig. 4c ), suggesting that the integrity of the tyrosine hydroxyl group is critical for the KLHL6 interaction. 
Flag-roquin2 Supplementary Fig. 8 , and statistical source data and exact P values for g,h can be found in Supplementary Table 6 . Unless otherwise noted, immunoblots are representative of three independent experiments.
We retrovirally transduced BJAB with roquin2(WT) or roquin2(Y691F) to investigate whether Tyr691 controls roquin2 stability in DLBCL cells. roquin2(Y691F) displayed increased protein levels at steady state as well as an increased half-life compared to roquin2(WT) ( Fig. 4f and Supplementary Fig. 4e ). Furthermore, KLHL6(WT) effectively downregulated protein levels of roquin2(WT), but not those of roquin2(Y691F) ( Supplementary  Fig. 4f ). The KLHL6 BTB-domain mutant (KLHL6(L65P)) had no effect on protein levels of roquin2(WT) and roquin2(Y691F) ( Supplementary Fig. 4f ).
Next, we analysed the effect of roquin2 stabilization on DLBCL growth. Expression of the non-degradable roquin2(Y691F) mutant increased tumour burden as monitored by tumour volume and weight at the experimental endpoint (Fig. 4g ). This effect was not an artifact of overexpression because the levels of roquin2(Y691F) were comparable to those of endogenous roquin2 in KLHL6 −/− cells ( Supplementary Fig. 4g ). Moreover, knockdown of roquin2 impaired the cell growth advantage of KLHL6 −/− U2932 and OCI-LY10 cells ( Fig. 4h and Supplementary Fig. 4h,i) . Importantly, loss of roquin2 increased toxicity of KLHL6 −/− cells preferentially ( Supplementary Fig. 4h ), suggesting that loss of KLHL6 promotes cell proliferation in a roquin2-dependent manner.
KLHL6 is a BCR/NF-κB target gene that links roquin2 degradation to BCR signaling. KLHL6 is a member of the B-cell receptor (BCR) signalosome 31 and is induced upon antigen stimulation in the germinal centre 3 . Thus, we investigated whether mRNA and protein levels of KLHL6 and roquin2 were affected by BCR stimulation. First, we found that ABC-DLBCL cells predominantly expressed an IgM-BCR as opposed to GCB-DLBCL cells, which are positive for IgG-BCR 32 (Supplementary Fig. 5a ). Subsequently, we analysed levels of KLHL6 and roquin2 in IgM-positive ABC-DLBCL cell lines (U2932, OCI-LY10 and HBL1) ( Fig. 5a ). BCR stimulation using fragment affinity-purified antibody F(ab′ ) 2 -IgM induced upregulation of KLHL6 and a corresponding downregulation of roquin2 protein levels in OCI-LY10 and U2932 cells, but not in HBL1 cells (a human cell line with low levels of both KLHL6 mRNA and KLHL6 protein (Fig. 5a) ).
To demonstrate that BCR-dependent downregulation of roquin2 protein depends on CRLs, we pre-treated U2932 cells with Supplementary Fig. 8 , and source data for a,c and statistical source data and exact P values for e can be found in Supplementary Table 6 . Unless otherwise noted, immunoblots are representative of three independent experiments.
MLN4924, a NEDD8-activating enzyme inhibitor that blocks cullin neddylation 33 . MLN4924 treatment rescued roquin2 downregulation induced by BCR crosslinking, suggesting that a functional CRL complex is required to promote roquin2 degradation (Fig. 5b) .
Notably, BCR stimulation induced KLHL6 upregulation both at transcriptional and protein levels ( Fig. 5a-c) . Because BCR signaling converges on NF-κ B activation 10 , we investigated whether KLHL6 is an NF-κ B target gene. Analysis of chromatin immunprecipitation followed by sequencing (ChIP-seq) datasets of NF-κ B factors 34 revealed enrichment of p50, p52, V-Rel avian reticuloendotheliosis viral oncogene homologue A (RelA) and B (RelB) at the KLHL6 gene locus (Fig. 5d ). Correspondingly, treatment of cells with an IKK or a BTK inhibitor (ibrutinib) 13 , resulted in a downregulation of KLHL6 both at mRNA and protein levels (Fig. 5e ). Interestingly, a reduced sensitivity of KLHL6 −/− cells to ibrutinib was observed ( Supplementary Fig. 5b ).
BCR-induced roquin2 degradation was impaired in KLHL6 −/− (Fig. 5f ) and KLHL6-knockdown cells ( Supplementary Fig. 5c,d) . Correspondingly, whereas exogenous roquin2(WT) was degraded in a dose-dependent manner upon BCR stimulation, roquin2(Y691F) mutant was not affected (Fig. 5g ), supporting BCR signaling promotes roquin2 degradation in a KLHL6-dependent manner.
Stabilization of roquin2 downregulates BCR responsive genes.
To investigate whether the pro-proliferative effect of the nondegradable roquin2(Y691F) mutant depends on its RNA binding ability, we generated a double mutant roquin2(Y691FΔ ROQ) that lacked the ROQ domain. Notably, deletion of the ROQ domain abolished the growth advantage induced by roquin2(Y691F) expression ( Fig. 6a ).
Next, we investigated whether misregulation of roquin2 degradation would result in a deregulation of the BCR transcriptional or HA-roquin2(Y691FΔ ROQ) treated with 10 μ g ml −1 of F(ab′ ) 2 -IgM for indicated times. The value of the PCR product at time 0 h was set to 1 for each condition. A representative graph from two independent experiments is shown. e, Left, qPCR analysis of TNFAIP3 mRNA in U2932 cells electroporated with indicated siRNAs and treated with actinomycin D for the indicated times. The value of the PCR product at time 0 h was set to 100%. Data are mean ± s.d., n = 3 independent experiments, two-way ANOVA, **P ≤ 0.01, ****P ≤ 0.0001, NS, not significant. Right, same analysis was performed in VAL cells expressing KLHL6 under a DOX-inducible promoter. Cells were pre-treated with DOX for 12 h and actinomycin D for the indicated times. Data are mean ± s.d., n = 3 independent experiments, two-way ANOVA, *P ≤ 0.05; ***P ≤ 0.001. Unprocessed scans of immunoblots in a are shown in Supplementary Fig. 8 , and source data for d and statistical source data and exact P values for a,e and b can be found in Supplementary Tables 6 and 3 , respectively. Unless otherwise noted, immunoblots are representative of three independent experiments.
program. We measured differential gene expression in U2932 cells expressing roquin2(WT) or roquin2(Y691F) upon BCR ligation via RNA-seq ( Fig. 6b and Supplementary Table 3 ). Pairwise comparison revealed that 133 mRNAs were significantly downregulated Supplementary Fig. 8, and source data for f and statistical source data for h-j and exact P values for j can be found in Supplementary Table 6 . Unless otherwise noted, immunoblots are representative of three independent experiments.
in roquin2(Y691F)-expressing cells compared to roquin2(WT). Of these 133 mRNAs, 64 overlapped with BCR-responsive genes defined as those with at least a twofold upregulation in expression upon BCR stimulation in cells expressing roquin2(WT) (Fig. 6b,c) . These 64 genes represented BCR-responsive genes that failed to be upregulated upon BCR stimulation in the presence of a nondegradable roquin2 mutant. Gene ontology enrichment analysis ( Supplementary Fig. 6a and Supplementary Table 4 ) revealed that roquin2-regulated genes are involved in immune and inflammatory responses and implicated as regulators of the NF-κ B pathway and lymphoid tumour suppressors (for example, TNF, NFKBIE, TNFAIP3, LTA and TNFRSF14.) 14, [35] [36] [37] [38] . To identify targets relevant to DLBCL biology, we ranked these genes by the percentage of genetic alterations in human DLBCL (TCGA (http://cancergenome.nih.gov/)) and the base mean expression in our RNA-seq analysis ( Supplementary Fig. 6b and Supplementary  Table 3 ). We validated the top 11 candidates in a secondary screen and found that 7 of these genese were dependent on a functional ROQ domain ( Supplementary Fig. 6b,c) .
Amongst these targets, we focused on TNFAIP3, because it is frequently inactivated in ABC-DLBCLs [12] [13] [14] [15] and is a direct target of the roquin proteins 19 . We found that TNFAIP3 was upregulated upon BCR stimulation, consistent with its function as a negative regulator of the NF-κ B 39 (Fig. 6d ). This response was abolished in cells expressing roquin2(Y691F), suggesting that stabilization of roquin2 contributes to a reduction in TNFAIP3 mRNA levels during BCR signaling. This effect was rescued partially in cells expressing roquin2(Y691FΔ ROQ), as a build-up of TNFAIP3 mRNA levels was observed. Notably, other NF-κ B target genes (NFKBIE and LTA) and the tumour suppressor gene TNFRSF14 displayed a similar pattern.
Lastly, we investigated whether the KLHL6-roquin2 axis directly controls TNFAIP3 mRNA stability. Ablation of KLHL6 shortened the half-life of TNFAIP3, which was partially rescued by concomitant ablation of roquin2 (Fig. 6e ). Re-expression of KLHL6(WT) in VAL cells, which carry endogenous mutations in the BTB-domain, also increased the half-life of TNFAIP3 (Fig. 6e) .
The KLHL6-roquin2 axis controls NF-κB activation. Because KLHL6 regulates TNFAIP3 mRNA levels, we hypothesized that loss of KLHL6 would lead to increased NF-κ B activation in ABC-DLBCL. First, we investigated whether the TNFAIP3 transcriptional changes would reflect similar changes in protein levels. BCR-dependent degradation of roquin2(WT) inversely correlated with the upregulation of TNFAIP3 levels, which was reduced in cells stably expressing roquin2(Y691F) (Fig. 7a ). Correspondingly, TNFAIP3 protein levels were downregulated in KLHL6 −/− cells, both at steady state and in response to BCR stimulation (Fig. 7b ). Knockdown of roquin2 in U2932 KLHL6 −/− cells rescued TNFAIP3 levels similar to those of KLHL6 +/+ cells ( Supplementary Fig. 7a ). Likewise, depletion of roquin2 more robustly upregulated TNFAIP3 protein levels in HBL1 cells (Fig. 7c) . Correspondingly, re-expression of KLHL6(WT) in U2932 KLHL6 −/− cells increased TNFAIP3 levels ( Supplementary Fig. 7b ).
Next, we investigated whether loss of KLHL6 resulted in increased IKK activation. The amount of Iκ Bα phosphorylation upon BCR stimulation was higher in KLHL6 −/− cells, suggesting increased IKK activity (Fig. 7d) . Importantly, the increase in phosphorylation was reduced after re-expression of KLHL6(WT) ( Supplementary Fig. 7c ). We also detected an increase in the nuclear translocation of the NF-κ B transcriptional factors in KLHL6 −/− cells (Fig. 7e) , which was partially mitigated by the concomitant knockdown of roquin2 ( Supplementary Fig. 7d ). Moreover, ablation of KLHL6 increased RelA DNA-binding at the NFKBIA promoter, an effect reversed by simultaneous knockdown of roquin2 (Fig. 7f) .
We analysed the mutual exclusivity of BTB-associated KLHL6 mutations with TNAFAIP3 alterations in DLBCL patients.
Deleterious mutations in the KLHL6 BTB-domain showed no overlap with TNFAIP3 biallelic deletion or mutation ( Fig. 7g and Supplementary Fig. 7e ). Using a weighted test 40 , we found exclusivity with a trend toward significance (P = 0.085, Supplementary  Table 5 ). Instead, four mutations in the BTB-domain had a coincident monoallelic deletion in TNFAIP3, suggesting that these mutations might confer additional NF-κ B activation when only one TNFAIP3 allele is lost. Interestingly, tumour cells from patients with KLHL6 mutations had a higher NF-κ B activity, although this signature was not only confined to cases in which KLHL6 was mutated ( Supplementary Fig. 7f ).
To investigate whether the tumour suppressor role of KLHL6 would be diminished in TNFAIP3-null ABC-DLBCLs, we ablated KLHL6 in RCK8 cells 14 and observed no significant effects on cellular proliferation (Fig. 7h ) and apoptosis (Fig. 7i) . Additionally, utilizing shRNAs targeting roquin2 in both HBL1 (wild-type TNFAIP3) and HLY1 (TNFAIP3-null 41 ) cells, we observed elevated apoptosis only in HBL1 cells (Fig. 7j) , indicating the relevance of roquin2 in cells harbouring a functional TNFAIP3 gene.
Discussion
KLHL6 is a BTB-kelch domain protein mutated in human DLBCL. Somatic mutations localize to the BTB-domain with relevant hotspots at amino acids 65 and 90 [4] [5] [6] [7] . Most KLHL6 alterations in DLBCL include monoallelic missense mutations and infrequent copy loss [4] [5] [6] [7] . Mutations in KLHL6 are probably the consequence of aberrant hypersomatic mutation 42 , similarly to those in BCL6 and MYC 43 . Importantly, the hotspots and other deleterious BTBdomain mutations result in loss of both cullin3 interaction and E3 ligase activity. Data from VAL cells suggest that mutations might be accompanied by transcriptional downregulation, resulting in a loss of function. Indeed, about 6% of DLBCL tumours showed downregulation of the KLHL6 transcript. In ABC-DLBCL cell lines, ablation of KLHL6 promotes cell growth both in vitro and in vivo, supporting a tumour suppressor role. These findings are consistent with low KLHL6 expression levels correlating with poorer survival in ABC-DLBCL patients 29, 30 .
Furthermore, we identified roquin2 as the bona fide substrate of KLHL6. KLHL6 specifically binds, ubiquitylates and triggers roquin2 (but not roquin1) degradation in a BCR-dependent manner. Expression of a non-degradable roquin2(Y691F) mutant phenocopies loss of KLHL6 and concomitant ablation of roquin2 in KLHL6 −/− cells results in an inhibition of cell proliferation. This pro-proliferative effect depends on the ability of roquin2 to bind RNA [18] [19] [20] [21] [22] . Although roquin1 and roquin2 are genetically redundant in the T-cell compartment 21 , no studies have assessed the functional redundancy in B-cell cancers. Transgenic mice overexpressing roquin2 or the non-degradable mutant in the germinal centre might be helpful to model the oncogenic role of roquin2 in DLBCL in vivo.
TNFAIP3 is a relevant target of roquin2-mediated mRNA decay 19 . In ABC-DLBCL, BCR-signaling triggers transcription of KLHL6 and degradation of roquin2, thus releasing TNFAIP3 from mRNA decay. We speculate that KLHL6-dependent inhibition of TNFAIP3 decay via roquin2 degradation contributes to establishing a negative feedback loop to terminate the NF-κ B signaling (Fig. 7k) . Thus, loss of KLHL6 function promotes BCR-dependent activation of NF-κ B in ABC-DLBCL. Correspondingly, mutations in KLHL6 correlate with high NF-κ B signatures and could serve as a marker of resistance to NF-κ B pathway-targeting drugs such as ibrutinib 13 , MLN4924 33 or bortezomib 1 .
TNFAIP3 genetic mutations and deletions are frequently observed in ABC-DLBCLs [12] [13] [14] [15] . Functional reconstitution of TNFAIP3 in TNFAIP3-null DLBCL causes apoptosis and growth arrest, supporting a tumour suppressor role in DLBCL 44, 45 . Interestingly, co-occurrence of mutations in the KLHL6 BTBdomain and biallelic deletion of or mutations in TNFAIP3 was rarely observed in human DLBCL, suggesting that these two genes may have similar downstream components (that is, IKK activation). A partial overlap between mutations in the KLHL6 BTB-domain and monoallelic deletion of TNFAIP3 further points to a possible synergy towards NF-κ B activation. On the other hand, neither roquin2 amplification nor sequence alteration of TNFAIP3 mRNA at the roquin2-binding site has been observed in DLBCLs. This suggests that the tumour suppressor mechanism of KLHL6 might extend beyond roquin2-TNFAIP3 deregulation. It is possible that KLHL6 might be involved in other biological processes such as cell adhesion, migration or immune surveillance in patients.
Much remains to be done to evaluate the functional impact of the KLHL6-roquin2 axis in GCB-DLBCLs, in which unknown KLHL6 substrates or different mRNA targets of roquin2 can contribute to the proliferation and survival of GCB-DLBCL cells. It is also worth noting that KLHL6 mutations are not observed at high frequency in non-B-cell cancers, suggesting a possibly differential role for KLHL6 in a different genetic and cellular context.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41556-018-0084-5.
Cell culture and drug treatment. HEK293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). U2932, BJAB, SUDHL4, SUDHL6, RAMOS, TMD8, HBL1, Pfeiffer, OCI-LY8, Karpas422, ARP1, RCK8, HLY-1, SUDHL10 and VAL cells were maintained in RPMI 1640 medium containing 10% FBS. OCI-LY1, OCI-LY7, OCI-LY10 and OCI-LY19 cells were maintained in Iscove's modified Dulbecco's Medium (IMDM) containing 10% FBS. For the BCR-crosslinking experiment, Goat-F(ab′ ) 2 antihuman IgM (SouthernBiotech, 2022-01) was used at the indicated concentrations. For the 3D Matrigel colony formation assay, 150 μ l of Corning Matrigel Basement Membrane Matrix was used in mix of 100 μ l of DMEM/F12 containing 10% knockout serum replacement and plated in Millicell EZ slides (Millipore). For quantification of cell numbers from colonies grown for 14 days, 300 μ l of Corning Dispase (354235) was used according to the manufacturers' protocols. The following drugs were used: proteasome inhibitor MG132 (Peptide Institute Inc., 10 μ M final concentration), cycloheximide (Sigma-Aldrich, 50 μ g ml −1 final concentration), MLN4924 (Active Biochem, 5 μ M final concentration), IKK-16 (Selleckchem, 10 μ M final concentration), ibrutinib (Selleckchem, 5 μ M final concentration), actinomycinD (Sigma-Aldrich, 2 μ g ml −1 final concentration), doxycycline hyclate (Sigma-Aldrich, 1 μ g ml −1 final concentration). When indicated, cells were selected with puromycin (Sigma-Aldrich, 0.5-1 μ g ml −1 final concentration) and hygromycin (ThermoFisher, 100 μ g ml −1 ). MTS assays (Promega, G5421) and AnnexinV staining (ThermoFisher AnnexinV, AlexaFluor-680 conjugate; A35109) were performed according to the manufacturers' protocols. For detection of IgM and IgG surface expression, FITC mouse anti-human IgM (BD, 562029) and APC mouse anti-human IgG (BD, 562025) were used according to the manufacturers' instructions.
Biochemical methods. Extract preparation, immunoprecipitation and immunoblotting, fractionation of DLBCLs and chromatin immunoprecipitation were carried out as previously described 46 . Band quantification was performed using ImageJ software and plotted using a nonlinear-fit curve in Graphpad Prism (Graphpad Prism 6). All antibodies were used at a dilution of 1:1,000 unless specified. The following antibodies were used: anti-Flag (Sigma-Aldrich, F7425, 1:3,000), anti-HA (Biolegend, 901513), anti-cullin1 (Invitrogen, 71-8700), anti-cullin3 (Bethyl Laboratories, A301-109A), anti-ubiquitin K48 (EMD Millipore, 05-1307), anti-roquin1/2 (EMD Millipore, MABF288), anti-roquin2 (Santa Cruz, sc-165026), anti-roquin2 (Bethyl Laboratories, A305-150A), anti-KLHL6 (Abcam, ab182163), anti-KLHL6 (Novus Biologicals, NBP1-46128), anti-tubulin (Santa Cruz, sc-8035), anti-GAPDH (EMD Millipore, MAB374, 1:5,000), anti-CDK1 (Santa Cruz, sc-954), anti-CDK2 (Santa Cruz, sc-163), anti-p-AKT S473 (Cell Signaling Technology, 4051), anti-p-ERK T202/Y204 (Cell Signaling Technology, 9101), anti-ERK1/2 (Cell Signaling Technology, 9102), anti-AKT (Cell Signaling Technology, 4691), anti-TNFAIP3 (Cell Signaling Technology, 5630), anti-p-Iκ B S32 (Cell Signaling Technology, 2859, 1:500), anti-p100/p52 (Cell Signaling Technology, 4882), anti-p105/p50 (Santa Cruz, sc-7178), anti-RelA (Santa Cruz, sc-372), anti-RelB (Santa Cruz, sc-226), anti-histone H2A (EMD Millipore, 07-146) and anti-histone H3 (Abcam, ab1791, 1:5,000), ECL rabbit IgG HRP-linked whole antibody (GE Healthcare, NA934-1ML, 1:5,000), ECL mouse IgG, HRPlinked whole antibody (GE Healthcare, NA931-1ML, 1:5,000), anti-rat IgG (H + L) polyclonal antibody (Jackson Immunoresearch, 112-035-003, 1:5,000), anti-goat IgG (H + L) polyclonal antibody (Jackson Immunoresearch, 705-035-003, 1:5,000). KLHL6, roquin1/2, TNFAIP3, cullin1, cullin3, p100/p52, p105/p50 and RelA antibodies were validated in our laboratory utilizing RNA interference as well as overexpression, and were also validated by the manufacturer. All other primary antibodies were validated on the manufacturer's datasheets.
The following agarose beads were used: anti-Flag-M2 affinity gel (Sigma-Aldrich, A2220) and Strep-Tactin Superflow 50% suspension (Neuromics).
Xenotransplantation experiments. All animal work was performed following the ethical guidelines and protocols approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania. NSG mice were purchased from the Jackson Laboratory. Six to eight-week-old NSG mice received subcutaneous flank injections of 1 × 10 7 U2932 KLHL6 −/− (clone-derived) cells that expressed empty vector, KLHL6(WT) or KLHL6(S94I)), and 1 × 10 7 U2932 cells infected with retroviruses encoding HA-roquin2(WT) or HA-roquin3H2(Y691F) in 100 µ l sterile PBS. Tumour burden was monitored weekly by palpation and visual inspection. Tumour volume was calculated by caliper measurement. Tumour weight was analysed on the excised tumours at the experimental endpoint using an analytical scale. After about one month, tumour volume and weight were measured.
Purification and analysis of KLHL6 interactors. Approximately 5 × 10 8 HEK293T and ARP-1 cells stably expressing Flag-tagged KLHL6(WT) or Flag-tagged KLHL6(L65P) cells were harvested and subsequently lysed in lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 50 mM NaF, 0.5% NP-40, plus protease and phosphatase inhibitors). KLHL6 was immunopurified with an anti-Flag agarose resin (Sigma-Aldrich) and washed five times with lysis buffer (15 min each). After washing, proteins were eluted with Flag peptides (Sigma-Aldrich). The eluates (1% of the immunoprecipitate) were separated by SDS-PAGE, and proteins were stained by silver staining (Life Technology). The final eluate was then precipitated with trichloroacetic acid.
In vitro ubiquitylation assay. The ubiquitylation of KLHL6 and roquin2 was performed in a volume of 10 µ l, containing 50 mM Tris pH 7.6, 5 mM MgCl 2 , 2 mM ATP, 1.5 ng µ l −1 E1 (Boston Biochem), 10 ng µ l −1 UBCH5C, 2.5 µ g µ l −1 ubiquitin (Sigma-Aldrich), 1 µ M ubiquitin aldehyde, and purified Flag-KLHL6 or Flag-KLHL6 and HA-roquin2 complex from HEK293T cells obtained by Flag immunoprecipitation. The reactions were incubated at 37 °C for the indicated times, subjected to SDS-PAGE, then analysed by immunoblot. When indicated, upon reaction, beads were resuspended in 1% SDS, boiled, then diluted to 0.1% SDS. The eluted proteins were further Flag-immunoprecipitated, washed and eluted in Laemmli buffer before SDS-PAGE analysis.
In vivo ubiquitylation assay. U2932 KLHL6 +/+ and KLHL6 −/− (clone-derived) cells were treated with or without MG132 for 6 h and lysed in 1% SDS. Lysates were then diluted to 0.1% SDS in NP-40 buffer and immunoprecipated with a polyclonal antibody against roquin2. The immunocomplexes were subjected to SDS-PAGE and analysed by immunoblot.
In vitro binding assays. For in vitro binding assays, in vitro-translated Flag-tagged KLHL6 was added to lysis buffer (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 0.1% Triton X-100, 1 mM EGTA) with indicated amounts of roquin2 peptides. Antistreptavidin resin was then added to the lysis buffer and incubated at 4 °C for 2 h. Samples were washed three times with the lysis buffer, and complexes were eluted in Laemmli buffer. For the use of HEK293T cells stably expressing KLHL6(WT), cells were lysed with the lysis buffer and anti-streptavidin resin was directly added to the whole-cell lysates with the peptides.
Transient transfections and retrovirus-mediated gene transfer. HEK293T cells were transfected using polyethylenimine. For retrovirus and lenvirius production, GP-293 packaging cells (Clontech) or pCMV-DeltaR8.2 were used respectively. The virus-containing medium was collected after 48 h of transfection and supplemented with 10 µ g ml −1 polybrene (Sigma-Aldrich). Then, cells were spininfected at 1,800 r.p.m. for 30 min with the viral supernatant for 6 h to overnight. For RCK8, cells were electroporated using Neon transfection system according to manufacturer's protocol with LentiCRISPRv2 vector carrying a GFP marker. Transfected cells were sorted by GFP. siRNA oligos transfection was performed with Neon transfection system. at a depth of at least 2 × 10 7 reads each. Reads were mapped and analysed with a custom bioinformatic pipeline based on STAR 63 , SAMTOOLS 64 and the R packages DEGseq 65 and DEseq2 66 . We used human genome version GRCh38 and gene annotations from the ENSEMBL release 83. Gene Ontology analyses were performed using version 6.8 of the DAVID web server 67, 68 .
ChIP-seq. The data discussed in this publication were obtained from the NCBI's Gene Expression Omnibus 34 and are accessible through GEO with series accession number GSE55105. FASTQs were downloaded and mapped to hg19 with Bowtie2 (v.2.1.0). Genome browser tracks were generated using custom scripts. When available, biological replicate were merged by taking the mean of the reads density at each position. The data were visualized using IGV 55 .
Statistics and reproducibility. All graphs show mean values with error bars signifying the standard deviation (s.d.) as indicated in the figure legends. Exact P values for each experiment are provided in Supplementary Table 6 . Unless otherwise noted, all immunoblots were successfully repeated at least three times. A one-tailed Student's t-test was performed for Fig. 3e (right panel) and a twotailed Student's t-test was used in Fig. 4g . Other analyses performed were one-way ANOVA (Figs. 3c,e (left panel), 5e,6a,7i,j and Supplementary Fig. 3b ,f) or two-way ANOVA (Figs. 1i,5b,d,3g ,h,6e,7h and Supplementary Figs. 2d, 3d, 4e ,h, 5b) as indicated in the figure legends. DEseq2 was performed for RNA-seq analysis in Fig. 6b and Supplementary Table 3 . Weighted exclusivity test was performed for Supplementary Table 5 . A Mantel-Cox test was performed for survival analysis in Fig. 3a . Pearson's correlation coefficient was used in Supplementary Fig. 2c .
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability.
RNA-seq data that support the findings of this study have been deposited in the Gene Expression Omnibus (GEO) under accession code GSE93675. Previously published ChIP-seq data were obtained from GEO under accession code GSE55105. KLHL6 copy number change and expression were calculated through re-analysis of SNP data and microarray from GSE11318, GSE12906, GSE15127, GSE22082, GSE34171 and GSE11318, GSE34171, respectively. Microarray data for DLBCL survival were obtained from GEO accession codes GSE10846, GSE34171, GSE31312. Data for NF-κ B signature correlation were retrieved from GSE10846. Raw mass spectrometry data are available from PRIDE (https://www.ebi.ac.uk/pride/archive/) under accession code PXD008963.
Raw data from independent experiments with n < 5 can be found in the statistical source data (Supplementary Table 6 ). Unprocessed immunoblots are provided in Supplementary Fig. 8 . All other data supporting the findings of this study are available from the corresponding author on reasonable request.
nature research | life sciences reporting summary

June 2017
Corresponding author(s): Luca Busino
Initial submission Revised version Final submission
Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined.
No statistical test was used to determine sample size and sample size was chosen based on literature.
Data exclusions
Describe any data exclusions.
No inclusion or exclusion criteria were used for samples or animals
Replication
Describe whether the experimental findings were reliably reproduced.
Attempts at replication were successful
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Biochemical and in vitro experiments did not need randomization, so this was not part of experimental design. In in vivo experiments utilizing mice, we randomly selected mice for subcutaneous injection.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were not blinded to allocation during experiments and outcome assessment. Blinding was not necessary as we used objective quantitative assays to generate the data.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
